WebSep 27, 2024 · The Custopharm acquisition complements Hikma’s injectable product portfolio and pipeline. Credit: v-a-n-3-ss-a / Pixabay. Hikma Pharmaceuticals has agreed to acquire US-based Custopharm from Water Street Healthcare Partners in a deal worth $425m to strengthen its injectables business in the country. WebOct 17, 2005 · Hikma Pharmaceuticals is a pharmaceutical manufacturer with a broad portfolio of generic, branded generic and in-licensed patented products. Use the CB …
Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride …
WebOur Products. We develop, manufacture and market branded and non-branded generic pharmaceutical medicines from two state-of-the-art manufacturing facilities in the US. … WebHikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. green ceramic glaze recipe earthenware
Hikma Pharmaceuticals Plc (HIK) - Research and Markets
WebWe are a trusted, reliable partner and dependable source of over 760 high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and … Web2 days ago · Generic drugmaker Hikma Pharmaceuticals Plc said on Wednesday Riad Mishlawi, president of the group's injectables business, will become its chief executive officer, effective Sept. 1. WebHikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North ... flow king rooter